Becton, Dickinson and (NYSE:BDX) Given New $295.00 Price Target at Morgan Stanley

Becton, Dickinson and (NYSE:BDXGet Rating) had its target price upped by Morgan Stanley from $293.00 to $295.00 in a report published on Monday morning, MarketBeat Ratings reports. They currently have an overweight rating on the medical instruments supplier’s stock.

Several other equities analysts have also recently issued reports on the company. Wells Fargo & Company lifted their price objective on Becton, Dickinson and from $275.00 to $285.00 and gave the stock an equal weight rating in a report on Friday, April 1st. Bank of America initiated coverage on Becton, Dickinson and in a report on Tuesday, March 1st. They set a neutral rating for the company. StockNews.com started coverage on Becton, Dickinson and in a report on Thursday, March 31st. They set a buy rating for the company. SVB Leerink boosted their price target on Becton, Dickinson and from $270.00 to $275.00 and gave the stock a market perform rating in a report on Friday, February 4th. Finally, Argus boosted their price target on Becton, Dickinson and from $275.00 to $310.00 in a report on Monday, February 28th. Six research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, Becton, Dickinson and currently has an average rating of Hold and an average price target of $276.25.

Becton, Dickinson and stock opened at $270.01 on Monday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.23 and a quick ratio of 0.78. Becton, Dickinson and has a 1-year low of $235.13 and a 1-year high of $280.62. The company has a market cap of $76.89 billion, a PE ratio of 46.71, a price-to-earnings-growth ratio of 3.37 and a beta of 0.65. The stock’s 50 day moving average price is $267.05 and its 200 day moving average price is $255.17.

Becton, Dickinson and (NYSE:BDXGet Rating) last issued its quarterly earnings data on Thursday, February 3rd. The medical instruments supplier reported $3.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.86 by $0.78. The firm had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.76 billion. Becton, Dickinson and had a return on equity of 14.87% and a net margin of 8.75%. Becton, Dickinson and’s revenue was down 6.0% on a year-over-year basis. During the same period in the previous year, the firm posted $4.55 earnings per share. On average, equities research analysts anticipate that Becton, Dickinson and will post 12.9 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 31st. Investors of record on Thursday, March 10th were paid a $0.87 dividend. The ex-dividend date was Wednesday, March 9th. This represents a $3.48 annualized dividend and a yield of 1.29%. Becton, Dickinson and’s payout ratio is currently 60.21%.

In related news, EVP Betty D. Larson sold 14,374 shares of the company’s stock in a transaction on Friday, February 25th. The stock was sold at an average price of $271.90, for a total value of $3,908,290.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Alexandre Conroy sold 6,410 shares of the company’s stock in a transaction on Thursday, February 3rd. The shares were sold at an average price of $270.16, for a total value of $1,731,725.60. The disclosure for this sale can be found here. Insiders sold 21,625 shares of company stock valued at $5,868,516 over the last quarter. Insiders own 0.50% of the company’s stock.

A number of hedge funds have recently bought and sold shares of BDX. Accel Wealth Management grew its position in Becton, Dickinson and by 100.0% during the fourth quarter. Accel Wealth Management now owns 100 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 50 shares during the period. Sierra Capital LLC grew its position in Becton, Dickinson and by 88.7% during the fourth quarter. Sierra Capital LLC now owns 100 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares during the period. Level Financial Advisors Inc. purchased a new stake in Becton, Dickinson and during the fourth quarter valued at about $26,000. Fortis Advisors LLC purchased a new stake in Becton, Dickinson and during the third quarter valued at about $27,000. Finally, Eagle Bay Advisors LLC grew its position in Becton, Dickinson and by 64.9% during the third quarter. Eagle Bay Advisors LLC now owns 155 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 61 shares during the period. 84.66% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Profile (Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

See Also

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.